Provigil Tapering Guide
modafinil
Overview
Modafinil is a wakefulness-promoting agent (eugeroic) approved for narcolepsy, obstructive sleep apnea, and shift work sleep disorder. It is widely prescribed off-label for fatigue, ADHD, and cognitive enhancement.
100mg, 200mg
Tablets: 100mg, 200mg
Avoid in pregnancy — recent data suggest increased risk of congenital malformations
Mechanism of Action
Mechanism is not fully understood. Modafinil weakly inhibits the dopamine transporter (DAT), increasing extracellular dopamine. It also affects orexin/hypocretin, histamine, norepinephrine, serotonin, and GABA systems involved in wakefulness regulation.
Taper Notes
Low classical dependence liability, but rebound fatigue and unmasking of underlying sleep pathology are common on discontinuation. A 2–4 week stepdown reduces rebound severity and allows the underlying condition (OSA, narcolepsy, shift-work disorder) to be addressed independently.
Maudsley Deprescribing Guidance
Not classically habit-forming, but abrupt cessation unmasks the underlying sleep disorder. Stepwise reductions over 2–4 weeks (e.g., 200 → 100 → 50 mg) combined with optimization of the underlying condition (CPAP, sleep hygiene, light therapy) reduce rebound severity.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reduction | 1-2 weeks | Reduce from 200 mg to 100 mg daily. Most patients tolerate this step without significant rebound. |
| Middle reduction | 1-2 weeks | Reduce to 50 mg (half-tablet) or alternate-day dosing using the 100 mg tablet. |
| Final discontinuation | 1-2 weeks | Discontinue. Concurrently optimize the underlying condition (CPAP adherence, sleep hygiene, scheduled napping) to mitigate rebound. |
Withdrawal Timeline
1-2 days after dose reduction
3-7 days
Typically within 1-2 weeks for most symptoms
Rebound fatigue and low mood may persist 2-4 weeks; underlying sleep disorders re-emerge if unaddressed
Clinical Pearls
Practical considerations for clinicians supervising Provigil tapers.
- 1Schedule the taper during a period of lower functional demand for the patient — rebound fatigue is clinically significant even when classical withdrawal is not.
- 2If modafinil is treating an underlying sleep disorder (OSA, narcolepsy), confirm that condition is independently optimized (CPAP adherence, scheduled naps) before discontinuation.
- 3Behavioral measures — hydration, morning light exposure, fixed wake time — substantially blunt the rebound period and should be in place before reductions begin.
- 4Modafinil is a CYP3A4 inducer; counsel patients on hormonal contraception to maintain backup contraception during therapy and for one month post-discontinuation while enzyme activity normalizes.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Hormonal contraceptives — modafinil induces CYP3A4 and reduces contraceptive efficacy; use additional contraception during and for 1 month after
- Cyclosporine and other CYP3A4 substrates — reduced exposure
- Warfarin — monitor INR (modafinil affects CYP2C9)
Food Interactions
- Food delays Tmax by ~1 hour but does not affect total exposure
- Avoid combining with high doses of caffeine or other stimulants
Contraindications
- Known hypersensitivity to modafinil or armodafinil
- History of left ventricular hypertrophy or mitral valve prolapse with prior stimulant-related symptoms
Toxicity
Severe rash including Stevens-Johnson syndrome (rare). Cardiovascular effects (tachycardia, hypertension). Psychiatric effects including mania, psychosis, and suicidal ideation.
Pharmacokinetics
ADME Profile
Rapidly absorbed, Tmax 2–4 hours. Food may delay absorption but does not affect overall bioavailability.
~0.9 L/kg
Hepatic metabolism, primarily via amide hydrolysis and CYP3A4 to inactive metabolites (modafinil acid, modafinil sulfone).
Renal (~80% as metabolites), <10% unchanged.
~60% (primarily albumin)
~50 mL/min
Build Provigil taper plans in minutes
TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.
Try TaperMeds